Target Engagement of D-cycloserine (DCS)

Status Not yet recruiting

Clinical Trial Summary

Assess the mechanism of action of d-cycloserine (DCS) to guide development of other medications working via similar molecular targets.

Clinical Trial Description

Evaluate the target engagement of DCS with Proton magnetic resonance spectroscopy (1H MRS) measurement of glutamate and glutamine (Glx) and GABA responses to DCS. The main purpose of the study will be to look at the acute effects of DCS on 1H MRS measured glutamate and gamma- aminobutyric acid (GABA), followed by an optional follow-up four week phase of lurasidone plus DCS and an magnetic resonance imagine (MRI) at the end of this four week treatment to assess both clinical and biomarker response to the four week treatment. Using combined DCS/lurasidone has potential unique synergies, with lurasidone blocking residual risk of psychosis with DCS, and DCS blocking akathisia associated with use of lurasidone or other atypical antipsychotics, along with potential synergistic antidepressive symptoms with the combination. There is an optional 4 week treatment with DCS + lurasidone following the MRI. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03401164
Study type	Interventional
Source	New York State Psychiatric Institute
Contact	Joshua T Kantrowitz, MD
Phone	646-774-6738
Email	Joshua.Kantrowitz@nyspi.columbia.edu
Status	Not yet recruiting
Phase	Phase 2
Start date	March 2018
Completion date	February 28, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05537558` - Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
Terminated	`NCT02192099` - Open Label Extension for GLYX13-C-202, NCT01684163	Phase 2
Completed	`NCT03142919` - Lipopolysaccharide (LPS) Challenge in Depression	Phase 2
Recruiting	`NCT05547035` - Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders	N/A
Terminated	`NCT02940769` - Neurobiological Effects of Light on MDD	N/A
Recruiting	`NCT05892744` - Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression	Phase 4
Recruiting	`NCT05537584` - SMART Trial to Predict Anhedonia Response to Antidepressant Treatment	Phase 4
Active, not recruiting	`NCT05061706` - Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder	Phase 3
Completed	`NCT04479852` - A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder	Phase 2
Recruiting	`NCT04032301` - Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans	Phase 1
Recruiting	`NCT05527951` - Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study	N/A
Completed	`NCT03511599` - Cycloserine rTMS Plasticity Augmentation in Depression	Phase 1
Recruiting	`NCT04392947` - Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation	N/A
Recruiting	`NCT05895747` - 5-HTP and Creatine for Depression R33 Phase	Phase 2
Recruiting	`NCT05273996` - Predictors of Cognitive Outcomes in Geriatric Depression	Phase 4
Recruiting	`NCT05813093` - Interleaved TMS-fMRI in Ultra-treatment Resistant Depression	N/A
Recruiting	`NCT05135897` - The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
Enrolling by invitation	`NCT04509102` - Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder	Early Phase 1
Recruiting	`NCT06145594` - EMA-Guided Maintenance TMS for Depression	N/A
Recruiting	`NCT06026917` - Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)	Phase 4